Published in Biol Reprod on March 01, 2002
Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe (2011) 1.72
Evolution of the hominoid semenogelin genes, the major proteins of ejaculated semen. J Mol Evol (2003) 1.14
Liquefaction of semen generates and later degrades a conserved semenogelin peptide that enhances HIV infection. J Virol (2014) 0.89
Vaginal swab specimen processing methods influence performance of rapid semen detection tests: a cautionary tale. Contraception (2010) 0.86
Peptidase activities in the semen from the ductus deferens and uterus of the neotropical rattlesnake Crotalus durissus terrificus. J Comp Physiol B (2009) 0.75
Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ (2009) 3.00
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Eur Urol (2007) 2.09
Hypothermia-treated cardiac arrest patients with good neurological outcome differ early in quantitative variables of EEG suppression and epileptiform activity. Crit Care Med (2009) 1.93
Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer (2011) 1.86
Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem (2009) 1.82
A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab (2005) 1.51
Specific immunoassay reveals increased serum trypsinogen 3 in acute pancreatitis. Clin Chem (2011) 1.44
Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma. Scand J Gastroenterol (2013) 1.44
High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol (2004) 1.41
Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer (2010) 1.41
Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res (2010) 1.33
Lead-time in prostate cancer screening (Finland). Cancer Causes Control (2002) 1.25
DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res (2010) 1.24
Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem (2003) 1.18
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
Vitamin D status as a determinant of peak bone mass in young Finnish men. J Clin Endocrinol Metab (2004) 1.14
Glycodelin: a major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation. Endocr Rev (2002) 1.13
High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer (2004) 1.12
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem (2006) 1.12
Sensitive protein detection via triple-binder proximity ligation assays. Nat Methods (2006) 1.11
Monitoring of seminoma patients with serum markers. Cancer (2013) 1.10
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol (2002) 1.10
Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab (2004) 1.09
Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer (2002) 1.09
Determination of 25-hydroxyvitamin D in serum by HPLC and immunoassay. Clin Chem (2003) 1.08
The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen. Eur Urol (2012) 1.08
Increased activity of the hypothalamic-pituitary-testicular axis in infancy results in increased androgen action in premature boys. J Clin Endocrinol Metab (2010) 1.08
Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology (2004) 1.06
Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry (2003) 1.04
Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography--electrospray mass spectrometry. Glycobiology (2006) 1.04
Glycodelin-A as a modulator of trophoblast invasion. Hum Reprod (2009) 1.04
Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells. Cancer Res (2002) 1.03
Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites. Clin Chem (2003) 1.03
Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab (2005) 1.02
CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol (2005) 1.01
Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol (2002) 1.01
Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst (2013) 1.01
Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.01
Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate (2008) 0.99
TBX6, LHX1 and copy number variations in the complex genetics of Müllerian aplasia. Orphanet J Rare Dis (2013) 0.98
Placental 11 beta-hydroxysteroid dehydrogenase-2 and fetal cortisol/cortisone shuttle in small preterm infants. J Clin Endocrinol Metab (2003) 0.98
Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate (2005) 0.96
Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res (2004) 0.95
Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci (2006) 0.95
IGF-I, IGF binding protein (IGFBP)-3, phosphoisoforms of IGFBP-1, and postnatal growth in very low birth weight infants. J Clin Endocrinol Metab (2002) 0.94
The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy. Urol Int (2010) 0.93
Rye whole grain and bran intake compared with refined wheat decreases urinary C-peptide, plasma insulin, and prostate specific antigen in men with prostate cancer. J Nutr (2010) 0.93
Maternal serum angiopoietin-1 and -2 and tie-2 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab (2009) 0.93
Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab (2006) 0.93
Glycodelin in ovarian serous carcinoma: association with differentiation and survival. Cancer Res (2003) 0.93
Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology (2003) 0.92
Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. Int J Cancer (2012) 0.92
Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer (2010) 0.91
Effects of differential glycosylation of glycodelins on lymphocyte survival. J Biol Chem (2009) 0.91
KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland. Eur Urol (2006) 0.91
In vivo assessment of the human sperm acrosome reaction and the expression of glycodelin-A in human endometrium after levonorgestrel-emergency contraceptive pill administration. Hum Reprod (2007) 0.91
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate (2005) 0.91
Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol (2002) 0.91
Determination of aldosterone in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.90
Pancreatic secretory trypsin inhibitor (SPINK1) gene mutations in patients with acute pancreatitis. Pancreas (2005) 0.90
Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors. J Reprod Med (2010) 0.89
SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer (2007) 0.89
The role of Chlamydia trachomatis infection in male infertility. Fertil Steril (2008) 0.89
Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin Cancer Res (2006) 0.89
False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. Clin Chem (2009) 0.88
Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab (2004) 0.88
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. J Gene Med (2007) 0.88
Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate (2002) 0.88
Cumulus oophorus-associated glycodelin-C displaces sperm-bound glycodelin-A and -F and stimulates spermatozoa-zona pellucida binding. J Biol Chem (2006) 0.88
Proximity ligation measurement of the complex between prostate specific antigen and alpha1-protease inhibitor. Clin Chem (2009) 0.88
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther (2007) 0.88
Preanalytical factors and reference intervals for serum hepcidin LC-MS/MS method. Clin Chim Acta (2011) 0.87
Technique for strand-specific gene-expression analysis and monitoring of primer-independent cDNA synthesis in reverse transcription. Biotechniques (2012) 0.87
Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. Ann Med (2008) 0.87
Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodelin in serum and endometrium during the luteal phase of the menstrual cycle. Contraception (2005) 0.87
Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma. Exp Cell Res (2007) 0.87
Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. Urology (2008) 0.86
Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors. J Pept Sci (2007) 0.86
Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol Chem (2008) 0.86
Effects of glycodelins on functional competence of spermatozoa. J Reprod Immunol (2009) 0.86
Mutations in two short noncoding mononucleotide repeats in most microsatellite-unstable colorectal cancers. Cancer Res (2005) 0.85
Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer (2004) 0.85
Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol (2007) 0.85
Binding of hepcidin to plasma proteins. Clin Chem (2012) 0.85
Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res (2004) 0.85